Treatment of diabetic kidney disease: current and future targets

키워드

참고문헌 (71)

1. 박철휘, "Diabetic Kidney Disease: From Epidemiology to Clinical Perspectives", Diabetes and Metabolism Journal, 38(4), pp.252~260 (2014), 대한당뇨병학회[DOI]
2. 안재희, "Prevalence and Determinants of Diabetic Nephropathy in Korea: Korea National Health and Nutrition Examination Survey", Diabetes and Metabolism Journal, 38(2), pp.109~119 (2014), 대한당뇨병학회[DOI]
3. Gregg EW, "Changes in diabetes-related complications in the United States, 1990-2010", N Engl J Med, 370, pp.1514~1523 (2014)
4. 이은정, "Diabetes in Asians", Endocrinology and Metabolism, 30(3), pp.263~269 (2015), 대한내분비학회
5. Parving HH, "Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective", Kidney Int, 69, pp.2057~2063 (2006)
6. Macisaac RJ, "Markers of and risk factors for the development and progression of diabetic kidney disease", Am J Kidney Dis, 63(2 Suppl 2), pp.S39~S62 (2014)
7. 김예니, "New therapeutic agents in diabetic nephropathy", The Korean Journal of Internal Medicine, 32(1), pp.11~25 (2017), 대한내과학회[DOI]
8. Muskiet MH, "The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?", Nat Rev Nephrol, 10, pp.88~103 (2014)
9. Diabetes Control and Complications Trial Research Group, "The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus", N Engl J Med, 329, pp.977~986 (1993)
10. UK Prospective Diabetes Study (UKPDS) Group., "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)", Lancet, 352, pp.837~853 (1998)
11. ADVANCE Collaborative Group, "Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes", N Engl J Med, 358, pp.2560~2572 (2008)
12. Stratton IM, "Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study", BMJ, 321, pp.405~412 (2000)
13. Zoungas S, "Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds", Diabetologia, 55, pp.636~643 (2012)
14. "Treatment guideline for diabetes: 2015" (2017)[URL]
15. American Diabetes Association., "5: Glycemic targets", Diabetes Care, 39(Suppl 1), pp.S39~S46 (2016)
16. National Kidney Foundation., "KDOQI clinical practice guideline for diabetes and CKD: 2012 update", Am J Kidney Dis, 60, pp.850~886 (2012)
17. Penno G, "Dipeptidyl peptidase-4inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury", Nutr Metab Cardiovasc Dis, 26, pp.361~373 (2016)
18. Panchapakesan U, "The role of dipeptidyl peptidase:4 inhibitors in diabetic kidney disease", Front Immunol, 6, pp.443~ (2015)
19. Solini A., "Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus", Acta Diabetol, 53, pp.863~870 (2016)
20. Gilbert RE., "Sodium-glucose linked transporter-2 inhibitors:potential for renoprotection beyond blood glucose lowering?", Kidney Int, 86, pp.693~700 (2014)
21. Zhong J, "An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control:potential implications in cardiovascular disease", Atherosclerosis, 226, pp.305~314 (2013)
22. Tiruppathi C, "Hydrolysis and transport of proline-containing peptides in renal brush-border membrane vesicles from dipeptidyl peptidase IV-positive and dipeptidyl peptidase IV-negative rat strains", J Biol Chem, 265, pp.1476~1483 (1990)
23. Mentlein R., "Dipeptidyl-peptidase IV (CD26): role in the inactivation of regulatory peptides", Regul Pept, 85, pp.9~24 (1999)
24. Sharkovska Y, "Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy", J Hypertens, 32, pp.2211~2223 (2014)
25. Yang J, "Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin", Life Sci, 81, pp.272~279 (2007)
26. Pala L, "Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells", Biochem Biophys Res Commun, 310, pp.28~31 (2003)
27. Mega C, "Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat)", Exp Diabetes Res, 2011, pp.162092~ (2011)
28. Marques C, "Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals", Mediators Inflamm, 2014, pp.538737~ (2014)
29. Liu WJ, "Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats", J Pharmacol Exp Ther, 340, pp.248~255 (2012)
30. 정권수, "Renoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice", Diabetes and Metabolism Journal, 40(3), pp.211~221 (2016), 대한당뇨병학회[DOI]
31. Kodera R, "Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes", Biochem Biophys Res Commun, 443, pp.828~833 (2014)
32. Kanasaki K, "Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen", Diabetes, 63, pp.2120~2131 (2014)
33. Gangadharan Komala M, "Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes", Nephrology (Carlton), 21, pp.423~431 (2016)
34. Hattori S., "Sitagliptin reduces albuminuria in patients with type 2 diabetes", Endocr J, 58, pp.69~73 (2011)
35. Fujita H, "DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1alpha in type 2 diabetic patients with incipient nephropathy", Endocr J, 61, pp.159~166 (2014)
36. White WB, "Alogliptin after acute coronary syndrome in patients with type 2 diabetes", N Engl J Med, 369, pp.1327~1335 (2013)
37. Scirica BM, "Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus", N Engl J Med, 369, pp.1317~1326 (2013)
38. Groop PH, "Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction", Diabetes Care, 36, pp.3460~3468 (2013)
39. Katz PM, "The role of the kidney and SGLT2inhibitors in type 2 diabetes", Can J Diabetes, 39(Suppl 5), pp.S167~S175 (2015)
40. Wanner C, "Empagliflozin and progression of kidney disease in type 2 diabetes", N Engl J Med, 375, pp.323~334 (2016)
41. Vallon V, "SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice", Am J Physiol Renal Physiol, 306, pp.F194~F204 (2014)
42. De Nicola L, "Sodium", glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes, 2014, pp.64, 16~24
43. Chilton R, "Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2diabetes", Diabetes Obes Metab, 17, pp.1180~1193 (2015)
44. Adler AI, "Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study", BMJ, 321, pp.412~419 (2000)
45. Patel A, "Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial", Lancet, 370, pp.829~840 (2007)
46. American Diabetes Association., "9: Microvascular complications and foot care", Diabetes Care, 39(Suppl 1), pp.S72~S80 (2016)
47. Taler SJ, "KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD", Am J Kidney Dis, 62, pp.201~213 (2013)
48. Kitada M, "Clinical therapeutic strategies for early stage of diabetic kidney disease", World J Diabetes, 5, pp.342~356 (2014)
49. Mann JF, "Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial", Lancet, 372, pp.547~553 (2008)
50. Brem AS, "Aldosterone-induced fibrosis in the kidney: questions and controversies", Am J Kidney Dis, 58, pp.471~479 (2011)
51. Hou J, "Spironolactone addon for preventing or slowing the progression of diabetic nephropathy: a meta-analysis", Clin Ther, 37, pp.2086.e10~2103.e10 (2015)
52. Pitt B, "Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial", Eur Heart J, 34, pp.2453~2463 (2013)
53. Bakris GL, "Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial", JAMA, 314, pp.884~894 (2015)
54. Gagliardini E, "Et and diabetic nephropathy:preclinical and clinical studies", Semin Nephrol, 35, pp.188~196 (2015)
55. Mann JF, "Avosentan for overt diabetic nephropathy", J Am Soc Nephrol, 21, pp.527~535 (2010)
56. Perez-Gomez MV, "Horizon 2020 in diabetic kidney disease: the clinical trial pipeline for add-on therapies on top of renin angiotensin system blockade", J Clin Med, 4, pp.1325~1347 (2015)
57. Shintani T, "Autophagy in health and disease:a double-edged sword", Science, 306, pp.990~995 (2004)
58. White E., "Deconvoluting the context-dependent role for autophagy in cancer", Nat Rev Cancer, 12, pp.401~410 (2012)
59. Masini M, "Autophagy in human type 2 diabetes pancreatic beta cells", Diabetologia, 52, pp.1083~1086 (2009)
60. Shinji Kume, "Autophagy: A Novel Therapeutic Target for Diabetic Nephropathy", Diabetes and Metabolism Journal, 39(6), pp.451~460 (2015), 대한당뇨병학회[DOI]
61. Kim SI, "Autophagy promotes intracellular degradation of type I collagen induced by transforming growth factor (TGF)-β1", J Biol Chem, 287, pp.11677~11688 (2012)
62. Yamahara K, "Obesity-mediated autophagy insufficiency exacerbates proteinuria-induced tubulointerstitial lesions", J Am Soc Nephrol, 24, pp.1769~1781 (2013)
63. Mizushima N, "In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker", Mol Biol Cell, 15, pp.1101~1111 (2004)
64. Bromann PA, "The interplay between Src family kinases and receptor tyrosine kinases", Oncogene, 23, pp.7957~7968 (2004)
65. Thomas SM, "Cellular functions regulated by Src family kinases", Annu Rev Cell Dev Biol, 13, pp.513~609 (1997)
66. Kopetz S, "Src continues aging:current and future clinical directions", Clin Cancer Res, 13, pp.7232~7236 (2007)
67. Mima A, "Angiotensin II-dependent Src and Smad1 signaling pathway is crucial for the development of diabetic nephropathy", Lab Invest, 86, pp.927~939 (2006)
68. Taniguchi K, "Inhibition of Src kinase blocks high glucose-induced EGFR transactivation and collagen synthesis in mesangial cells and prevents diabetic nephropathy in mice", Diabetes, 62, pp.3874~3886 (2013)
69. Yan Y, "Src inhibition blocks renal interstitial fibroblast activation and ameliorates renal fibrosis", Kidney Int, 89, pp.68~81 (2016)
70. Zhou D, "Therapy for kidney fibrosis: is the Src kinase a potential target?", Kidney Int, 89, pp.12~14 (2016)
71. Seo HY, "Fyn deficiency attenuates renal fibrosis by inhibition of phospho-STAT3", Kidney Int, 90, pp.1285~1297 (2016)

관련 논문AI추천